21 results about "Microbial host" patented technology

The present disclosure is generally related to the fields of microbial host cells, molecular biology, protein engineering, fermentation, protein production, and the like. Certain aspects of the disclosure are related to novel promoter and 5′-untranslated region a nucleic acid (DNA) sequences.

The invention discloses a method and system for synchronously detecting host chromatin openness and in-vivo microbiome based on transposase, and belongs to the technical field of biological sequencing data analysis. According to the method, transposase is used for selectively fragmenting an open chromatin region of a host, and a microbial genome is almost randomly cut, so that synchronous enrichment of host and microbial DNA is realized; after high-throughput sequencing library construction and double-end sequencing, sequencing data is split into host source and non-host source reads through bioinformatics analysis, host chromatin state and microorganism composition are analyzed respectively, and a microorganism-host epigenetic regulation network is constructed; the invention further provides a matched DNA sequencing library and an analysis system, multi-scene research of infectious diseases, intestinal microecology, tumor microenvironment and the like is supported, a public database can be reanalyzed, and potential microbial interaction signals are mined. According to the method, the host-microorganism interaction research efficiency is remarkably improved, and a high-sensitivity and integrated technical scheme is provided for epigenetic regulation mechanism analysis.

This invention discloses a plasmid for gene overexpression in non-pattern *Bacillus laterosporus*. Its leader region contains a methyltransferase expression cassette derived from the *Bacillus laterosporus* i83 genome, enabling stable existence in specific hosts containing the RM system. Based on this, a PidR2 promoter is added to obtain the pMCPidR2 shuttle plasmid. The PidR2 promoter effectively drives target gene expression, the pWV01 replicon ensures plasmid replication in non-pattern hosts, and the chloramphenicol resistance gene is used for positive colony selection. The plasmid contains a TraJ element, allowing it to be introduced into non-pattern microbial hosts via conjugation transfer. This invention also provides a target gene expression strategy in non-pattern microorganisms, achieving high transformation efficiency and high strain yield through conjugation transfer transformation of donor bacteria, conjugation transfer helper bacteria, and recipient bacteria, resulting in stable expression of the target protein. This invention provides an effective vector for efficient and stable gene overexpression in specific non-pattern microorganisms, helping to solve the problem of difficult genetic manipulation of industrial production strains.

The present invention relates to methods and compositions for preventing erroneous incorporation of n-leucine into a protein during the production of a recombinant protein in a bacterium. The invention also provides microbial host cells and nucleic acid molecules for use in the methods and compositions provided herein.

The present invention introduces an innovative approach for the manipulation of microorganisms to generate colored bioplastics. This is achieved by concurrently expressing genes responsible for pigment production and genes involved in bioplastic synthesis within a microbial host. These genes can be synthesized, obtained from a different host through cloning, or naturally occurring within the host organism. The resultant color compounds become encapsulated within the extended bioplastic polymers within the cells, resulting in the formation of naturally pigmented bioplastics.

Embodiments of the present invention provides recombinant systems, methods, and compositions for the biological production of Testosteronan (Testan), a linear α-(1→4)-linked glucuronic acid–N-acetylglucosamine polysaccharide. Microbial hosts engineered to express full-length CtTS, N-terminal truncation variants (including d64-CtTS), or the Pseudomonas CIPTS homolog synthesize high–molecular-weight Testan (≥800 kDa) with low polydispersity. Structural analysis by ¹H NMR and 2D HSQC demonstrates that all recombinant enzymes produce Testan that is chemically indistinguishable from native polymer. Purification using ultrafiltration and strong-anion exchange chromatography yields highly defined molecular-weight fractions, including monodisperse populations (PDI ~1.02). The invention further provides sulfated derivatives of Testan produced via aqueous sulfation methods, as well as Testan and functionalized Testan compositions useful for chromatographic stationary phases, biomaterial scaffolds, and chemically modifiable polymer platforms. These systems provide the first scalable, fermentation-based production methods for Testan and Testan-derived materials.

The present invention relates to polypeptide comprising an immunoglobulin single variable domain (ISVD) that specifically binds and inhibits a urease, which ISVD is modified to improve one or more of its protease resistance, thermostability, producibility in microbial hosts and in situ performance in animal excreta. Alone or in combination, the ISVD's of the invention are able to inhibit a broad range of microbial and plant-based ureases. The urease-inhibiting polypeptides of the invention can be used in compositions such as animal feed, animal feed premixes and supplements, to be fed to animals, for reducing the amount of ammonia released from the animal and / or for reducing the amount of ammonia released from the animal's excreta, with the aim to reduce ammonia emissions from agriculture into atmosphere and / or ecosystems. In addition, in the polypeptides can be used in an environmental application like stable floors, slurry pits and urea-based fertilizers for reducing the emission of ammonia.

The invention relates to the technical field of biological medicines, in particular to an ACT structural domain protein derived from coprobacterium rodent and application of the ACT structural domain protein in preparation of anti-tumor and anti-radiation medicines. The invention provides ACT structural domain protein. The amino acid sequence of the ACT structural domain protein is shown as SEQ ID NO: 2. As a functional protein derived from intestinal probiotics, the ACT structural domain protein provided by the invention provides a new molecular probe and a research object for revealing an action mechanism of intestinal flora in tumor generation and development. The protein not only provides an entry point for research on interaction of intestinal microecology and tumor immunity, but also lays a foundation for development of novel biomarkers and drug targets based on microbiome, and has important scientific value in the research field of tumor biology and microorganism-host interaction.

he present disclosure describes a genetically modified microbial host cell expressing and secreting a compound of interest, wherein the cell comprises a native gene involved in the regulation of secretion from the cell of the compound of interest with a signal peptide and / or without a signal peptide wherein the native gene has been modified to alter its functionality in the cell whereby the secretion and yield of the compound of interest from the cell is increased compared to a cell where the gene has not been modified.

Provided are: a transformant capable of improving the productivity of 3-HBA; and a method for producing 3-HBA using said transformant. In one aspect, the present disclosure pertains to a transformant for producing 3-hydroxybenzoic acid (3-HBA), the transformant being obtained by expressibly introducing, into a microbial host having chorismic acid-producing ability, a gene (A) encoding an enzyme (3-HBA synthase) having activity for producing 3-HBA from chorismic acid, wherein the microbial host is Corynebacterium glutamicum. In another aspect, the present disclosure pertains to a method for producing 3-HBA, the method comprising a step for culturing this transformant to produce 3-HBA.

The invention discloses application of a cytidine triphosphate synthetase mutant in cytidine production, and belongs to the technical field of recombinant microorganisms. According to the invention, site-specific mutagenesis is carried out on a pyrG gene for coding cytidine triphosphate synthetase, and the 152nd amino acid of a protein coded by the pyrG gene from W3110 is mutated into alanine, so that the mutant pyrG is obtained. Recombinant plasmids carrying the mutant gene are transformed into microbial host bacteria (such as escherichia coli or bacillus subtilis), and the expression level and / or catalytic activity of CTP synthetase can be remarkably improved, so that a speed limiting step in a cytidine synthesis route is eliminated, and more metabolic flows are guided to biosynthesis of cytidine. Compared with an unmodified strain, the cytidine yield of the engineering strain constructed by the method disclosed by the invention can be increased by more than 20%. The method is accurate and efficient, the uncertainty caused by traditional random mutagenesis is avoided, and a technical scheme with important application value is provided for industrial production of cytidine.

This document discloses methods for producing interfering RNA (RNA) biopesticides, such as microbial host organisms engineered to produce interfering RNA molecules that inhibit gene expression in disease-carrying mosquitoes through RNA interference. This document also discloses polynucleotides, such as expression cassettes encoding these interfering RNA molecules and facilitating integration (e.g., stable integration) into the host organism's genome. This document further discloses compositions comprising the disclosed nucleotide sequences and a host organism, and methods for using them to control mosquito populations.

The present invention relates to mutant galactoside permeases, in particular microbial host cells and fermentation processes employing mutant galactoside permeases that display reduced or abolished proton-coupled transport activity while retaining substrate translocation. These permease variants, when expressed at levels exceeding endogenous wild-type expression, enable cultivation and production processes, in particular in the presence of elevated lactose concentrations without the growth limitations typically associated with lactose-induced energetic collapse. The invention further relates to genetic constructs, metabolic pathways, and process strategies suitable for the production of lactose-based products, such as human milk oligosaccharides.

The instant disclosure provides, inter alia, novel nucleases comprising enhanced performance properties. In certain embodiments, the disclosure is therefore related to nucleases having enhanced performance properties (benefits), nuclease compositions and protein preparations thereof, recombinant polynucleotides (expression construct) encoding mature nuclease of the disclosure, recombinant microbial host cells expressing / producing / secreting nucleases of the disclosure, recombinant microbial host cells co-expressing / co-producing nucleases and proteins of interest, and the like.

Disclosed herein are methods for producing interfering RNA larvicides for Spotted Wing Drosophila, D. suzukii, such as microbial host organisms engineered to produce interfering RNA (iRNA) molecules which selectively undermine the survival of female D. suzukii larva, to produce a predominantly male population of adult SWD flies. Such iRNA molecules selectively inhibit the expression of a gene in female SWD larvae population by RNA interference. Also disclosed herein are polynucleotides, such as expression cassettes encoding iRNA molecules and facilitating integration, such as stable integration into the genome of a host cell. Further disclosed herein are compositions including the disclosed nucleotide sequences and host organisms, along with methods of using the same to generate a predominately male SWD population.

The invention relates to the technical field of genomics and metabonomics, in particular to a substance for relieving intestinal injury of crisp tilapia and an application effect analysis method of the substance. According to the invention, the tauroursodeoxycholic acid (TUDCA) is applied to relieving intestinal inflammation damage caused by feed embrittlement of the crisp tilapia for the first time, and intestinal inflammation is relieved. By establishing a three-dimensional evaluation system of'intestinal histomorphology + metabonomics + metagenomics', the relieving effect of TUDCA on intestinal inflammation is systematically quantified. Through combined analysis of intestinal metabolome and metagenome, a'microorganism-host interaction 'health judgment model is constructed, and the maintenance of the quality of fish meat after inflammation is relieved is verified through muscle texture parameters, so that a'repair-evaluation-quality maintenance' closed-loop technical scheme is formed.

The present invention relates to arecombinant microbial host cell producing a tetraketide or derivatives thereof from one or more substrates selected from cinnamoyl-CoA, p-Coumaroyl-CoA, Caffeoyl-CoA, Feruloyl-CoA, malonyl-CoA, sinapoyl-CoA and dihydro derivatives thereof, comprising an operative biosynthetic metabolic pathway for the tetraketide or derivatives thereof comprising a chalcone isomerase-like (CHIL) polypeptide heterologous to the host cell and a Type 3 polyketide synthase (PKS).

Embodiments of the present invention provides recombinant systems, methods, and compositions for the biological production of Testosteronan (Testan), a linear α-(1→4)-linked glucuronic acid–N-acetylglucosamine polysaccharide. Microbial hosts engineered to express full-length CtTS, N-terminal truncation variants (including d64-CtTS), or the Pseudomonas CIPTS homolog synthesize high–molecular-weight Testan (≥800 kDa) with low polydispersity. Structural analysis by ¹H NMR and 2D HSQC demonstrates that all recombinant enzymes produce Testan that is chemically indistinguishable from native polymer. Purification using ultrafiltration and strong-anion exchange chromatography yields highly defined molecular-weight fractions, including monodisperse populations (PDI ~1.02). The invention further provides sulfated derivatives of Testan produced via aqueous sulfation methods, as well as Testan and functionalized Testan compositions useful for chromatographic stationary phases, biomaterial scaffolds, and chemically modifiable polymer platforms. These systems provide the first scalable, fermentation-based production methods for Testan and Testan-derived materials.

Methods and systems for bioproduction of panthenol in microbial hosts and cell-free are provided, which include a pantothenate synthetase (PanC) enzyme that is engineered for improved activity and increased panthenol production.

The present invention relates to methods for the production of oligosaccharides in genetically modified bacterial host cells, as well as to the genetically modified host cells used in the methods. The genetically modified host cell comprises at least one recombinant glycosyltransferase, and at least one nucleic acid sequence coding for a protein enabling the export of the oligosaccharide.

The present disclosure relates to promoters engineered to increase responsiveness to C2 carbon sources. Engineered promoters comprise at least one external carbon source responsive element (CSRE) located upstream and proximal to a transcription initiation site of a gene operably associated therewith. The engineered promoters can be used in heterologous nucleic acid molecules, vectors, or expression cassettes to promote expression of genes in microorganisms. The disclosure also relates to methods for producing the engineered promoters and methods for expressing genes in recombinant microbial host cells using the engineered promoters.